Use of core 2 G1cNAc transferase inhibitors in treating inflammation
AssigneeThe Regents of the University of California
InventorsJamey D. Marth, Lesliey G. Ellies
Life of this patent
Estimating the term…
Abstract
This invention provides compounds and methods for treating inflammation. The compounds modulate the core 2 oligosaccharide-mediated binding of inflammatory cells, such as neutrophils, to endothelial cells and other myeloid cells. Significantly, the of the invention methods block inflammation without affecting lymphocyte trafficking. In some embodiments, the compounds inhibit the activity of a core 2 GlcNAc transferase that is involved in synthesizing the core 2 oligosaccharides.
Claims12
A method of inhibiting an inflammatory response in a mammal, the method comprising administering to the mammal a compound that is an analog of a core 2 GlcNAc transferase acceptor substrate and inhibits the activity of the core 2 GlcNAc transferase, thereby inhibiting the inflammatory response in the mammal.
A method of inhibiting binding of a first myeloid cell to an endothelial cell or to a second myeloid cell, the method comprising contacting the first myeloid cell with a compound that is an analog of a core 2 GlcNAc transferase acceptor substrate and inhibits the core 2 GlcNAc transferase, thereby inhibiting synthesis of a core 2 oligosaccharide.
Dependencies are inferred from the claim text.